J&J Settles Days Before Risperdal Trial
After years of litigation and several court losses for harm caused by Risperdal, Johnson & Johnson’s legal team agreed to settle the suit of a young boy from Mississippi who claims he developed female-like breasts after taking the drug Risperdal. The plaintiff began taking Risperdal in 2004 after he was tentatively diagnosed with bipolar disorder. J&J […]
“Major Step Forward” in Opioid Suits
“I did a little math. About 150 Americans are going to die today, just today, while we’re meeting.” -Judge Dan Polster October 5, 2018, U.S. Magistrate Judge David Ruiz of the Northern District of Ohio submitted for approval his report and recommendation in a key a case involving the opioid crisis to U.S. District Judge […]
HHS Pick, Former Eli Lilly Exec, Grilled over Zyprexa Scandal
News: Trials Begin October 2015
Sheller, P.C. law firm Risperdal cases continue, with trials beginning October, 2015. From the daily newspaper The Legal Intelligencer: “A second wave of trials in the Risperdal mass tort has been scheduled for October, and several more cases are gearing up for trials in the spring. Two trials against Janssen Pharmaceuticals, the maker of the […]
Risperdal News: Sheller Quoted in Toronto Star
Stephen Sheller was quoted in a July 31, 2015 article discussing Risperdal research that was “manipulated by a drug company and understated the risks of a powerful antipsychotic used to treat kids with behavioural problems.” In the news story, pediatrician Denis Daneman says there was no intent on his part to exclude “significant results” from […]
$520 MILLION SETTLEMENT
April 27, 2010: In the third record whistleblower settlement for Sheller, P.C. in fifteen months, the firm represented a whistleblower who brought forth knowledge of wrongdoing by AstraZeneca. AstraZeneca agreed to a civil settlement of $520 million for charges of off-label marketing of the powerful antipsychotic drug Seroquel. The settlement is the largest pharmaceutical civil settlement […]
#1 PA V&S 2013-2014
Sheller, P.C. had the largest settlement in Pennsylvania in 2013-2014 as published in American Lawyer Media’s Legal Intelligencer newspaper. The $2.2 billion settlement with Janssen Pharmaceuticals, a division of Johnson & Johnson, was a qui tam case where Sheller, P.C. represented the whistleblower who brought the qui tam charges. With the U.S. Department of Justice, […]
$2.2B Settlement “Leads the Pack”
The $2.2 Billion Settlement with Johnson & Johnson Leads the Pack by Lizzy McLellan, The Legal Intelligencer The Legal Intelligencer reported that the largest verdict and settlement award in Pennsylvania between August 2013 and August 2014 was handled by Sheller, P.C. with a $2.2 billion settlement over healthcare giant Johnson & Johnson and its subsidiary, […]
$58.9 MILLION SETTLEMENT
The Sheller whistleblower team announced a $58.9 milllion settlement with Shire Pharmaceuticals over off-label marketing of ADHD drugs Adderall and Vyvanse in September, 2014. Court documents detailing the civil allegations and settlement were signed by Shire and unsealed by the Office of the United States Attorney for the Eastern District of Pennsylvania. A Shire executive, […]
$2.2 Billion Settlement
With the $2.2B Risperdal settlement, Sheller, P.C.’s representation of whistleblowers totals over $6.4 billion, with three of the top five pharmaceutical settlements in history 2009: Pfizer $2.3 billion (Geodon) 2009: Eli Lilly & Co. $1.4 billion (Zyprexa) 2013: Johnson & Johnson $2.2 billion (Risperdal, Invega) 2010 : Astra Zeneca $520 million (Seroquel) WASHINGTON, November 4, […]
